TY - JOUR
T1 - Cancer of unknown primary site
T2 - A review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a Single Institute in Japan
AU - Nishimori, Hisakazu
AU - Takahashi, Shunji
AU - Kiura, Katsuyuki
AU - Ennishi, Daisuke
AU - Kobayashi, Takayuki
AU - Sano, Koji
AU - Shinozaki, Eiji
AU - Yokoyama, Masahiro
AU - Mishima, Yuko
AU - Terui, Yasuhito
AU - Chin, Keisho
AU - Mizunuma, Nobuyuki
AU - Ito, Yoshinori
AU - Nishimura, Seiichiro
AU - Takeuchri, Kengo
AU - Ishikawa, Yuichi
AU - Oguchi, Masahiko
AU - Tanimoto, Mitsune
AU - Hatake, Kiyohiko
PY - 2010
Y1 - 2010
N2 - We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.
AB - We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosuppression and hyponatremia. The MST of all 28 patients with CUP was 8.3 months, and the 1-year overall survival rate was 45.6%. Univariate analysis identified 5 prognostic factors:performance status, liver involvement, bone involvement, pleural involvement, and lymph node involvement. In conclusion, CDDP/TXT chemotherapy is effective with tolerable toxicity in patients with CUP. Japanese patients with CUP might be chemosensitive and may survive longer.
KW - Cancer of unknown primary site (CUP)
KW - Cisplatin
KW - Docetaxel
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=78149433869&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78149433869&partnerID=8YFLogxK
M3 - Article
C2 - 20975761
AN - SCOPUS:78149433869
SN - 0386-300X
VL - 64
SP - 285
EP - 291
JO - Acta Medica Okayama
JF - Acta Medica Okayama
IS - 5
ER -
